⌕
Takeda Pharmaceutical · TAK · NYSE
Tenet 32 · Weak
Compare
$21.59+0.75%At closeTenet 32 · Weak
$21.59+0.16 (+0.75%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD

Takeda Pharmaceutical (TAK) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● ReutersNov 12, 2026 · 07:38 ET
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle

Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle…

● Business WireNov 12, 2026 · 07:35 ETCOMPANY'S OWN WORDS
Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1, is Now Available in the United States.…

● Defense WorldNov 3, 2026 · 03:55 ET
Takeda Pharmaceutical Co. $TAK Shares Sold by Heritage Investors Management Corp

Heritage Investors Management Corp cut its holdings in shares of Takeda Pharmaceutical Co. (NYSE: TAK) by 63.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exc…

● Seeking AlphaOct 30, 2026 · 07:29 ET
Takeda Pharmaceutical's Earnings Growth Has Yet To Translate To Higher Cash Flow

Takeda Pharmaceutical is reiterated as a Hold, with concerns about its ability to replace major drug revenues and current valuation. Operating margin improved to 17% due to lower amortization, but operating cash flow dec…

● MarketBeatOct 30, 2026 · 07:15 ET
What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings Call

Takeda Pharmaceutical NYSE: TAK reported first-half fiscal 2026 results that management said were in line with expectations as the company invested in new product launches and its late-stage pipeline while using savings …

● BenzingaOct 29, 2026 · 12:46 ET
Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang

Takeda Pharmaceutical Co Ltd (NYSE:TAK) on Thursday reported second-quarter adjusted earnings of 48 cents per share, beating the consensus of 31 cents.…

● Seeking AlphaOct 29, 2026 · 11:08 ET
Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript

Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript…

● Business WireOct 29, 2026 · 02:36 ETCOMPANY'S OWN WORDS
Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026). The period included the approval of ORZEYFUL (oveporexton…

● Business WireOct 23, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patie…

● Business WireOct 19, 2026 · 05:30 ET
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-f…

● Business WireOct 14, 2026 · 20:30 ET
Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first a…

● Business WireOct 14, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda presents Phase 2/3 study results for TAK-881 in primary immunodeficiency (PID), showing comparability to HYQVIA with 50% less IG volume.…

● Seeking AlphaOct 13, 2026 · 15:48 ET
Takeda Remains A Buy, Boosted By Recent Narcolepsy Drug Approval And Robust Pipeline

Takeda gets its prior buy rating reaffirmed. Positive factors are recent drug approval, robust future pipeline, global reach, and an investment-grade rating. TAK serves several clinical areas, filling specific medical ne…

● Defense WorldOct 1, 2026 · 04:15 ET
Critical Contrast: ProPhase Labs (NASDAQ:PRPH) & Takeda Pharmaceutical (NYSE:TAK)

Takeda Pharmaceutical (NYSE: TAK - Get Free Report) and ProPhase Labs (NASDAQ: PRPH - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the streng…

● Defense WorldSep 30, 2026 · 02:44 ET
Takeda Pharmaceutical (NYSE:TAK) vs. RYTHM (NASDAQ:RYM) Financial Survey

RYTHM (NASDAQ: RYM - Get Free Report) and Takeda Pharmaceutical (NYSE: TAK - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of thei…

● Business WireSep 30, 2026 · 01:00 ET
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation, highly selectiv…

● Business WireSep 29, 2026 · 08:00 ET
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium

BOSTON--(BUSINESS WIRE)--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium.…

● ReutersSep 23, 2026 · 01:12 ET
Roche proposes former Takeda CEO for board seat

Roche on Wednesday ​said it ‌was proposing Christoph Weber, the ​former ​CEO of Takeda Pharmaceuticals , ⁠for election ​to the ​Swiss company's board of directors at ​its AGM ​next March.…

● Business WireSep 22, 2026 · 09:30 ETCOMPANY'S OWN WORDS
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress…

● Business WireSep 18, 2026 · 01:00 ETCOMPANY'S OWN WORDS
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the com…

● ReutersSep 17, 2026 · 23:41 ET
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

Dr Reddy's ​Laboratories ‌said on ​Friday ​it signed a ⁠deal ​with ​Takeda Pharmaceutical Company ​for ​the promotion and ‌distribution ⁠of the Qdenga ​dengue ​vaccine ⁠in ​India.…

● Defense WorldSep 16, 2026 · 01:15 ET
Takeda Pharmaceutical (NYSE:TAK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Financial Contrast

Takeda Pharmaceutical (NYSE: TAK - Get Free Report) and Teva Pharmaceutical Industries (NYSE: TEVA - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies b…

● Seeking AlphaSep 14, 2026 · 19:01 ET
Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● Zacks Investment ResearchSep 14, 2026 · 07:06 ET
Best Value Stocks to Buy for September 14th

SIG, TAK and TX made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 14th, 2026.…

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just TAK · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.